GSK stock
Price history
+6.31% over the period1 year: from 1,799.50 GBp (November 17, 2025) to 1,913.00 GBp (November 17, 2026), +6.31%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | 1,913.00 GBp |
| October 30, 2026 | 1,855.00 GBp |
| September 30, 2026 | 1,832.00 GBp |
| August 28, 2026 | 1,853.50 GBp |
| July 31, 2026 | 1,931.50 GBp |
| June 30, 2026 | 1,981.00 GBp |
| May 29, 2026 | 1,881.50 GBp |
| April 30, 2026 | 1,928.50 GBp |
| March 31, 2026 | 2,064.00 GBp |
| February 27, 2026 | 2,201.00 GBp |
| January 30, 2026 | 1,876.50 GBp |
| December 31, 2025 | 1,824.50 GBp |
| November 28, 2025 | 1,791.00 GBp |
| November 17, 2025 | 1,799.50 GBp |
At a glance
The company
Develops and manufactures vaccines, specialty medicines, and general medicines to prevent and treat diseases globally
Latest results
Quarter to September 30, 2026 · EPS £0.55 (estimate £0.51)
TickerLandia's take on GSK
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 14 vs a median of 17 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 18 vs 22 (−16%) in a group of 10.
- Strong point: Dividend (71/100 in its group). Weak point: Growth (23/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−18.10% from the 52-week high
Analysts · 23 analysts
Average target2,147.38 GBp+14.89% vs. price
Buy 7 · Hold 13 · Sell 3 · Hold
TickerLandia Fingerprint: GSK
Compared with similar companies: low growth, low price, and low financial strength.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow27
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 18.0 28 Forward P/E 10.3 15 EV/EBITDA 8.51 22 Price/book 4.12 44 Price/sales 2.31 26 Profitabilityaverage51
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 73.8% 50 Net margin 13.0% 34 ROE 28.3% 73 Operating margin 30.5% 50 ROA 9.6% 46 Earnings stabilityaverage52
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.6% 50 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthlow23
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +4.00% 12 Earnings growth (year over year) −22.80% 15 Average revenue growth (3 years) +3.66% 42 Financial strengthlow27
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.17 42 Interest coverage 14.4 42 Current ratio 0.86 6 Debt/equitycounts in reverse: lower means more financial strength 1.30 19 Dividendhigh71
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 34 years 76 Payout ratio 64.5% 60 Dividend yield 3.5% 77 Market momentumaverage43
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +0.15% 53 Relative strength (6 months) −5.31% 47 1-year return +3.86% 40 Distance from 200-day average −4.37% 32 Riskaverage55
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.4% 47 Beta (1 year) 1.00 72 Maximum drawdown (12 months) 23.5% 47
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
GSK is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), GSK's P/E today is 13.8, below the median of its last 10 fiscal years (17.2; between 3.93 and 84.6 from 2016 to 2025). GSK's P/E (trailing 12 months): 18.0, −16% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | GSK | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 18.0 | Low | |
| Forward P/E | 10.3 | Low | |
| Operating margin | 30.5% | Middle | |
| ROE | 28.3% | Middle | |
| Debt/equity | 1.30 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: GSK. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
£8.89B
Latest quarter · Q3 2026
Net income
£1.54B
Latest quarter · Q3 2026
Quarterly net margin
17.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- £77.35B
- P/E
- 18.0
- EPS
- 107.00 GBp
- Volume
- 3.7M
- Daily trading
- €147.98M
- Dividend yield
- 3.69%
- Last ex-dividend on November 12, 2026
How GSK is changing
All resultsRevenue grew 6.0% a year on average over the last 5 years
Operating margin rose from 21.9% to 24.3%
Profits turn into cash: free cash flow equal to 129% of net income
Returns
GSK returns with dividends
£1,000 invested in GSK 5 years ago, on November 17, 2021, would be worth £1,520 today with dividends reinvested: +52.01% in total, +8.74% per year. On price alone it would be £1,218 (+21.81%).
| Period | GSK | FTSE 100 | £1,000 becomes |
|---|---|---|---|
| 1 month | +3.13% | +0.38% | £1,031 |
| 6 months | +0.35% | +5.98% | £1,003 |
| Year to date | +4.85% | +8.80% | £1,049 |
| 1 year | +10.11% | +11.68% | £1,101 |
| 3 years | +52.31% | +43.99% | £1,523 |
| 5 years | +52.01% | +48.20% | £1,520 |
| 10 years | +112.35% | +59.02% | £2,123 |
Over the last 6 months it has done better than 16% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment
The chart in detail
GSK: technical analysis
GSK shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 18.9% below its highest close since January 1, 1990 (2,304.83 GBp, January 8, 1999).
- Trend
- No clear trend
- RSI (14 sessions)
- 49
- Between 30 and 70
- vs 200-session average
- −4.37%
Support and resistance
Price areas where GSK has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance2,053.35 GBp+9.86%2 touches, last on July 6, 2026
- Resistance1,979.75 GBp+5.93%2 touches, last on August 10, 2026
- Resistance1,910.14 GBp+2.20%7 touches, last on October 27, 2026
- Last price1,869.00 GBp
- Support1,852.00 GBp−0.91%2 touches, last on July 21, 2026
- Support1,804.00 GBp−3.48%2 touches, last on August 14, 2026
- Support1,778.00 GBp−4.87%5 touches, last on October 28, 2026
Volatility and risk
Over the last year it has moved roughly in line with the FTSE 100.
- Beta (1 year) vs FTSE 100
- 1.00
- Volatility (60 sessions, annualised)
- 26.4%
- Largest fall in the last year
- −23.48%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
GSK: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for GSK has been December: +1.95% on average, positive in 23 years out of 36. The weakest has been January: −0.98% on average, positive in 14 years out of 36. November, the current month, has been positive in 17 years out of 36 (−0.02% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.98% | −1.32% | 14 of 36 |
| February | +0.20% | +0.56% | 20 of 37 |
| March | +1.28% | +0.68% | 22 of 37 |
| April | +1.88% | +2.04% | 23 of 37 |
| May | −0.68% | −0.67% | 17 of 37 |
| June | +0.25% | +1.07% | 23 of 37 |
| July | +0.15% | +0.09% | 19 of 37 |
| August | +0.31% | +0.53% | 22 of 37 |
| September | +0.55% | +0.24% | 21 of 37 |
| October | +1.46% | +1.04% | 20 of 37 |
| November | −0.02% | −0.56% | 17 of 36 |
| December | +1.95% | +2.02% | 23 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
GSK and its competitors
Shingles, RSV and HPV vaccines, HIV medicines, and inhalers for asthma and COPD are the products most people associate with the group. Its work covers vaccines, specialty medicines and general medicines, and it also develops oral small-molecule therapies for oncology and inflammatory diseases. Customers are in the United Kingdom, the United States and other markets abroad, and its collaborations include an mRNA vaccine project with CureVac and a tuberculosis alliance with AN2 Therapeutics.
- Headquarters
- London, United Kingdom
- Employees
- 66,841
- Founded
- 1715
- Chief executive
- Luke Miels
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| GSKGSK | $102.04B | 30.5% | 18.0 | +0.35% |
| SanofiSAN | $116.52B | 22.3% | 25.5 | +17.04% |
| BayerBAYN | $61.54B | 16.5% | — | +48.87% |
| Novo NordiskNOVO.B | $184.87B | 50.8% | 11.2 | −7.92% |
| AstraZenecaAZN | $287.12B | 25.8% | 26.6 | +1.25% |
| NovartisNOVN | $305.16B | 34.0% | 32.6 | +14.23% |
Same industry or related industries, similar size. Compare GSK with its competitors · Full profile
